The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19
Patients with long COVID and acute COVID should benefit from treatment with H.E.L.P. apheresis, which is in clinical use for 37 years. COVID-19 can cause a severe acute multi-organ illness and, subsequently, in many patients the chronic illness long-COVID/PASC. The alveolar tissue and adjacent capil...
Main Authors: | Beate Roxane Jaeger, Hayley Emma Arron, Wiltrud M. Kalka-Moll, Dietrich Seidel |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1007636/full |
Similar Items
-
Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a)
by: Tina Z. Khan, et al.
Published: (2021-01-01) -
Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
by: Jan Torzewski, et al.
Published: (2022-03-01) -
Selective Apheresis of C-Reactive Protein for Treatment of Indications with Elevated CRP Concentrations
by: Stefan Kayser, et al.
Published: (2020-09-01) -
Dose- and time-related platelet response with apheresis platelet concentrates and pooled platelets
by: Mohammad Mizanur Rahman, et al.
Published: (2017-02-01) -
Extracorporeal LDL-Cholesterol Elimination in the Treatment of Severe Familial Hypercholesterolemia
by: Milan Bláha
Published: (2003-01-01)